ZA202307855B - Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome - Google Patents

Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Info

Publication number
ZA202307855B
ZA202307855B ZA2023/07855A ZA202307855A ZA202307855B ZA 202307855 B ZA202307855 B ZA 202307855B ZA 2023/07855 A ZA2023/07855 A ZA 2023/07855A ZA 202307855 A ZA202307855 A ZA 202307855A ZA 202307855 B ZA202307855 B ZA 202307855B
Authority
ZA
South Africa
Prior art keywords
tasquinimod
treatment
pharmaceutically acceptable
acceptable salt
myelodysplastic syndrome
Prior art date
Application number
ZA2023/07855A
Other languages
English (en)
Inventor
Wobus Manja
Sockel Katja
Bornhäuser Martin
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of ZA202307855B publication Critical patent/ZA202307855B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ZA2023/07855A 2021-01-18 2023-08-11 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome ZA202307855B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21152018 2021-01-18
EP21201509 2021-10-07
EP21205665 2021-10-29
PCT/EP2022/050891 WO2022152902A1 (en) 2021-01-18 2022-01-17 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Publications (1)

Publication Number Publication Date
ZA202307855B true ZA202307855B (en) 2025-12-17

Family

ID=80034981

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2023/07855A ZA202307855B (en) 2021-01-18 2023-08-11 Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome

Country Status (12)

Country Link
US (1) US20240091215A1 (https=)
EP (1) EP4277628B1 (https=)
JP (1) JP7837338B2 (https=)
KR (1) KR20230133317A (https=)
AU (1) AU2022208424A1 (https=)
CA (1) CA3204120A1 (https=)
ES (1) ES3057099T3 (https=)
IL (1) IL304232A (https=)
MX (1) MX2023008016A (https=)
PL (1) PL4277628T3 (https=)
WO (1) WO2022152902A1 (https=)
ZA (1) ZA202307855B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4346773T3 (pl) 2021-05-25 2025-11-03 Active Biotech Ab Duża liczba cząstek taskwinimodu i ich zastosowanie
WO2024137713A1 (en) * 2022-12-20 2024-06-27 Constellation Pharmaceuticals, Inc. Methods for treating lower risk myelodysplastic syndrome

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9801474D0 (sv) 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
SE9802549D0 (sv) 1998-07-15 1998-07-15 Active Biotech Ab Quinoline derivatives
SE0002320D0 (sv) 1999-10-25 2000-06-21 Active Biotech Ab Malignant tumors
SE0201778D0 (sv) 2002-06-12 2002-06-12 Active Biotech Ab Process for the manufacture of quinoline derivatives
US7189740B2 (en) * 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
SE0400235D0 (sv) 2004-02-06 2004-02-06 Active Biotech Ab New composition containing quinoline compounds
SG186430A1 (en) 2010-07-09 2013-01-30 Active Biotech Ab Method for manufacturing of quinoline-3-carboxamides
EP2537517A1 (en) 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
EP3711484A1 (en) * 2013-07-05 2020-09-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Soluble cd33 for treating myelodysplastic syndromes (mds)
KR20160136323A (ko) * 2014-02-28 2016-11-29 인사이트 코포레이션 골수형성이상증후군 치료용 jak1 억제제
JP6647287B2 (ja) * 2014-09-23 2020-02-14 アクティブ バイオテック エイビー 多発性骨髄腫の治療に使用するためのキノリンカルボキサミド
MX379401B (es) * 2014-11-19 2025-03-11 Active Biotech Ab Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
EP3067062A1 (en) 2015-03-13 2016-09-14 Ipsen Pharma S.A.S. Combination of tasquinimod or a pharmaceutically acceptable salt thereof and a pd1 and/or pdl1 inhibitor, for use as a medicament
EA202090655A1 (ru) * 2017-10-06 2020-12-07 Тесаро, Инк. Комбинированные терапевтические средства и их применение
JP2019127473A (ja) * 2018-01-26 2019-08-01 学校法人同志社 多発性硬化症の治療及び／又は予防のための薬剤

Also Published As

Publication number Publication date
CA3204120A1 (en) 2022-07-21
EP4277628C0 (en) 2025-09-24
WO2022152902A1 (en) 2022-07-21
IL304232A (en) 2023-09-01
EP4277628A1 (en) 2023-11-22
AU2022208424A1 (en) 2023-08-24
JP7837338B2 (ja) 2026-03-30
KR20230133317A (ko) 2023-09-19
PL4277628T3 (pl) 2026-02-09
JP2024503372A (ja) 2024-01-25
ES3057099T3 (en) 2026-02-26
EP4277628B1 (en) 2025-09-24
AU2022208424A9 (en) 2024-05-09
US20240091215A1 (en) 2024-03-21
MX2023008016A (es) 2023-07-13

Similar Documents

Publication Publication Date Title
ZA202107579B (en) Pharmaceutical combinations for the treatment of cancer
MX2021006011A (es) Un inhibidor de la quinasa aurora a para su uso en el tratamiento del neuroblastoma.
NZ763551A (en) Compounds useful for inhibiting cdk7
PH12018502742A1 (en) Glucagon derivative, conjugate thereof, composition comprising same and therapeutic use thereof
EP4497474A3 (en) Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
TN2019000210A1 (en) Antitumoral compounds
GEP20197011B (en) Heteroaryl compounds for kinase inhibition
ZA202307855B (en) Tasquinimod or a pharmaceutically acceptable salt thereof for use in the treatment of myelodysplastic syndrome
MX2023011176A (es) Tratamiento de hidradenitis supurativa con orismilast.
MY203645A (en) Ret inhibitor for use in treating cancer having a ret alteration
MX2015014958A (es) Nuevos derivados de triazolona o sales de la misma y composicion farmaceutica que comprende a la misma.
IL288864A (en) Treatment that includes sglt inhibitors, for example sglt 1/2 inhibitors
EA202091169A1 (ru) Применяемые в качестве ингибиторов iap миметики smac и их применение
PH12021551138A1 (en) Application of chidamide in combination with r-chop, and drug combination
MX2023013148A (es) Iptacopan para el tratamiento del sindrome uremico hemolitico atipico.
MX2020003427A (es) Agentes terapeuticos para enfermedades neurodegenerativas.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
ZA202004849B (en) Therapeutic agents for treating restless legs syndrome
PH12022551578A1 (en) Prophylactic and/or therapeutic agent for chronic prostatitis/chronic pelvic pain syndrome
MX2021009663A (es) Tratamiento del sindrome de pitt-hopkins.
WO2019203748A3 (en) The composition comprising raloxifene with at least one antipsychotic agent
WO2019190427A3 (en) The immediate release combination comprising raloxifene and at least one antipsychotic agent
EP4335508A3 (en) (+)-azasetron for use in the treatment of ear disorders
HK40075891A (en) Treatment for sjögren's syndrome